• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MR contrast patterns predict therapy response

Article

The permeability of gadolinium and the morphology of breast cancers can reliably predict whether those tumors will benefit from neoadjuvant chemotherapy, according to a study by researchers at Duke University.

The permeability of gadolinium and the morphology of breast cancers can reliably predict whether those tumors will benefit from neoadjuvant chemotherapy, according to a study by researchers at Duke University.

The vascularity of tumors and their reaction to blood-borne contrast predict a likely response to therapy. Tumors that were closely packed with cancer cells did not effectively retain contrast and were resistant to chemotherapy, said Oana Craciunescu, Ph.D., a Duke radiation oncologist, who reported the study results at the San Antonio Breast Cancer Symposium in December.

Tumors in which the blood vessels formed a ring pattern around the center were also resistant to chemotherapy because collapsed blood vessels in the center would not carry the drug there. The best responders were homogeneous tumors in which blood vessels were evenly distributed throughout the tumor.

Recent Videos
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.